Metropolitan Life Insurance Company (MetLife)’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,632
| Closed | -$46.1K | – | 2055 |
|
|
2024
Q1 | $46.1K | Sell |
2,632
-53
| -2% | -$928 | ﹤0.01% | 1447 |
|
|
2023
Q4 | $58.5K | Hold |
2,685
| – | – | ﹤0.01% | 1360 |
|
|
2023
Q3 | $41.2K | Buy |
2,685
+377
| +16% | +$5.78K | ﹤0.01% | 1515 |
|
|
2023
Q2 | $54.9K | Buy |
2,308
+261
| +13% | +$6.21K | ﹤0.01% | 1367 |
|
|
2023
Q1 | $52.1K | Sell |
2,047
-293
| -13% | -$7.45K | ﹤0.01% | 1365 |
|
|
2022
Q4 | $68.4K | Buy |
2,340
+748
| +47% | +$21.8K | ﹤0.01% | 1281 |
|
|
2022
Q3 | $32.7K | Hold |
1,592
| – | – | ﹤0.01% | 1743 |
|
|
2022
Q2 | $18.4K | Buy |
+1,592
| New | +$18.4K | ﹤0.01% | 2080 |
|